- First Online:
- 680 Downloads
Rasagiline (Azilect®), a selective, irreversible, monoamine oxidase-B inhibitor, is available in the EU, the US and in several other countries worldwide, including Canada and Israel. It is indicated for the treatment of idiopathic Parkinson’s disease as monotherapy or as adjunctive therapy to levodopa in patients with end-of-dose fluctuations in the EU and for the treatment of adult patients with the signs and symptoms of idiopathic Parkinson’s disease in the US. This article reviews the pharmacological properties, therapeutic efficacy and tolerability of rasagiline as monotherapy or as adjunctive therapy to levodopa in patients with Parkinson’s disease.
Oral rasagiline as monotherapy or as adjunctive therapy to levodopa was effective in the symptomatic treatment of adult patients with Parkinson’s disease participating in double-blind, placebo-controlled, multinational studies. In patients with early Parkinson’s disease, monotherapy with rasagiline 1 mg/day (recommended dosage) significantly slowed the rate of worsening (i.e. an increase in the Unified Parkinson’s Disease Rating Scale [UPDRS] score) in the ADAGIO and TEMPO studies, with the results from the ADAGIO study for rasagiline 1 mg/day suggesting a slowing of clinical progression. However, at the higher dosage of 2 mg/day, rasagiline met the primary endpoint in the TEMPO study and the first, but not the second, of three hierarchical primary endpoints in the ADAGIO study. Compared with delayed-start rasagiline monotherapy, early initiation was associated with a slower long-term progression of the clinical signs and symptoms of Parkinson’s disease in the TEMPO study. As adjunctive therapy to levodopa in the LARGO and PRESTO studies, rasagiline 0.5 and/or 1 mg/day significantly reduced the total daily ‘off’ time (primary efficacy endpoint) and significantly improved the Clinical Global Impression score, the UPDRS activities of daily living subscale score during ‘off’ time and the UPDRS motor subscale score during ‘on’ time compared with placebo in patients with advanced Parkinson’s disease.
Although rasagiline showed neuroprotective properties both in vitro and in vivo, identifying its potential to slow clinical progression in the clinical setting has been elusive to date and was not definitively demonstrated in the studies discussed in this article. Additional rasagiline studies specifically designed to assess the clinical progression of Parkinson’s disease while addressing the potentially confounding factors of the delayed-start study design would therefore be of interest.
As monotherapy or as adjunctive therapy to levodopa, rasagiline was generally well tolerated, with the frequency and nature of treatment-emergent adverse events generally similar across clinical studies and between rasagiline and placebo groups. Therapy with rasagiline appears to be associated with a low incidence of cognitive and behavioural adverse events.
Thus, oral rasagiline as monotherapy or as adjunctive therapy to levodopa provides a useful option in the treatment of adult patients with Parkinson’s disease.
- 2.Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Medical, 2011Google Scholar
- 10.Teva Pharma GmbH. Rasagiline (Azilect®): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000574/WC500030048.pdf [Accessed 2011 Apr 12]
- 11.Teva Neuroscience Inc. Azilect® (rasagiline mesylate) tablets for oral use: prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf [Accessed 2011 Apr 12]
- 20.Teva Pharmaceutical Industries Ltd. Data on file. 2011 DecGoogle Scholar
- 22.Chen JJ, Panisett M, Rhyee S. Rasagiline and antidepressant use in patients with Parkinson’s disease: assessing the occurrence of serotonin toxicity [abstract]. 2011 Annual Meeting of the American College of Clinical Pharmacy; 2011 Oct 16–19; Pittsburgh (PA)Google Scholar
- 23.Teva Pharmaceutical Industries Ltd. Investigation of the occurrence of serotonin toxicity in Parkinson’s Disease (PD) patients treated concomitantly with rasagiline and antidepressants, using retrospective chart review [Clinical-Trials.gov identifier NCT00955604]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2012 Jan 19]
- 78.Plus supplementary material available from URL: http://www.nejm.org/ [Accessed 2011 Mar 8]
- 32.Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011 May; 10(5): 415–23PubMedCrossRefGoogle Scholar
- 35.Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005 Mar; 365(9463): 947–54PubMedCrossRefGoogle Scholar
- 41.Teva Pharmaceutical Industries Ltd. Teva announces Health Canada approves Azilect® (rasagiline) for Parkinson’s disease [online]. Available from URL: http://www.tevapharm.com/en-US/Media/News/Pages/2006/1557352. aspx [Accessed 2012 Jan 31]
- 42.Teva Pharmaceutical Industries Ltd. Teva announces that Azilect® (rasagiline) is approved for marketing in Israel [online]. Available from URL: http://www.tevapharm.com/en-US/Media/News/Pages/2005/1557104.aspx [Accessed 2012 Jan 31]
- 45.National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35). London: NICE, 2006 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/10984/30088/30088.pdf [Accessed 2011 Jul 27]
- 46.Oertel WH, Berardelli A, Bloem BR, et al. Early (uncomplicated) Parkinson’s disease. In: Gilhus NE, Barnes MP, Brainin M, editors. European handbook of neurological management. 2nd ed. Oxford: Wiley-Blackwell, 2011; 1: 217–36Google Scholar
- 47.Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson’s disease: a national clinical guideline (SIGN publication no. 113). Edinburgh: SIGN, 2010 JanGoogle Scholar
- 48.Oertel WH, Berardelli A, Bloem BR, et al. Late (complicated) Parkinson’s disease. In: Gilhus NE, Barnes MP, Brainin M, editors. European handbook of neurological management. 2nd ed. Oxford: Wiley-Blackwell, 2011; 1: 237–67Google Scholar
- 49.Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease. An evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002 Jan; 58(1): 11–7Google Scholar
- 54.Ahlskog JE, Uitti RJ. Reply to Drs. Olanow and Rascol [letter]. Neurology 2010 Apr; 74(14): 1151Google Scholar
- 55.Montgomery Jr EB. The delayed-start study in Parkinson disease: can’t satisfy everyone. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? [letter]. Neurology 2010 Nov; 75(21): 1943; author reply 1944-5Google Scholar
- 56.Schwarzschild MA. The delayed-start study in Parkinson disease: can’t satisfy everyone. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? [letter]. Neurology 2010 Nov; 75(21): 1943–4; author reply 1944-5Google Scholar
- 58.Teva Pharmaceutical Industries Ltd. ADAGIO follow up study: evaluation of the long-term effects of rasagiline in Parkinson’s disease subjects [ClinicalTrials.gov identifier NCT00936676]. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2012 Jan 27]